These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33446324)

  • 1. Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets.
    Reva BA; Omelchenko T; Nair SS; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e9-e16. PubMed ID: 33446324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
    de Almeida DVP; Fong L; Rettig MB; Autio KA
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32343604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of checkpoint inhibitors in prostate cancer: drugs for the many but useful to a few.
    F Slovin S
    Immunotherapy; 2020 Mar; 12(4):219-221. PubMed ID: 32172641
    [No Abstract]   [Full Text] [Related]  

  • 4. Gastrointestinal cancer stem cells as targets for innovative immunotherapy.
    Chivu-Economescu M; Necula LG; Matei L; Dragu DL; Neagu AI; Alexiu I; Bleotu C; Diaconu CC
    World J Gastroenterol; 2020 Apr; 26(14):1580-1593. PubMed ID: 32327907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of immune escape in the cancer immune cycle.
    Tang S; Ning Q; Yang L; Mo Z; Tang S
    Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade.
    Bonavita E; Bromley CP; Jonsson G; Pelly VS; Sahoo S; Walwyn-Brown K; Mensurado S; Moeini A; Flanagan E; Bell CR; Chiang SC; Chikkanna-Gowda CP; Rogers N; Silva-Santos B; Jaillon S; Mantovani A; Reis e Sousa C; Guerra N; Davis DM; Zelenay S
    Immunity; 2020 Dec; 53(6):1215-1229.e8. PubMed ID: 33220234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tackling Resistance to Cancer Immunotherapy: What Do We Know?
    Gondhowiardjo SA; Handoko ; Jayalie VF; Apriantoni R; Barata AR; Senoaji F; Utami IJW; Maubere F; Nuryadi E; Giselvania A
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    Bou-Dargham MJ; Sha L; Sang QA; Zhang J
    BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor activity in T cells limits checkpoint blockade efficacy.
    Guan X; Polesso F; Wang C; Sehrawat A; Hawkins RM; Murray SE; Thomas GV; Caruso B; Thompson RF; Wood MA; Hipfinger C; Hammond SA; Graff JN; Xia Z; Moran AE
    Nature; 2022 Jun; 606(7915):791-796. PubMed ID: 35322234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    De Velasco MA; Kura Y; Fujita K; Uemura H
    Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon gamma in cancer immunotherapy.
    Ni L; Lu J
    Cancer Med; 2018 Sep; 7(9):4509-4516. PubMed ID: 30039553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications.
    Hargadon KM
    Br J Dermatol; 2021 Dec; 185(6):1095-1104. PubMed ID: 34185875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the tumor-immune microenvironment in prostate cancer.
    Dong L; Myers KV; Pienta KJ
    Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VISTA: A promising target for overcoming immune evasion in gynecologic cancers.
    Liu S; Ji F; Ding Y; Ding B; Feng S; Brennick C; Lin H; Zhang T; Shen Y
    Int Immunopharmacol; 2024 Sep; 138():112655. PubMed ID: 38986302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibition in Prostate Cancer.
    Nicholson LT; Fong L
    Trends Cancer; 2020 Mar; 6(3):174-177. PubMed ID: 32101720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging principles of brain immunology and immune checkpoint blockade in brain metastases.
    Fares J; Ulasov I; Timashev P; Lesniak MS
    Brain; 2021 May; 144(4):1046-1066. PubMed ID: 33893488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape from IFN-γ-dependent immunosurveillance in tumorigenesis.
    Lin CF; Lin CM; Lee KY; Wu SY; Feng PH; Chen KY; Chuang HC; Chen CL; Wang YC; Tseng PC; Tsai TT
    J Biomed Sci; 2017 Feb; 24(1):10. PubMed ID: 28143527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
    Ajina R; Zahavi DJ; Zhang YW; Weiner LM
    Semin Cancer Biol; 2020 Oct; 65():28-37. PubMed ID: 31866479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
    Kim TJ; Koo KC
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.